Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PD-L1/VEGF bispecific vs PD-1 antibody with chemotherapy in locally advanced NSCLC
ChiCTR2600124154Phase 3Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Pathologic complete response (pCR). Planned start May 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600124154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124154.